Gilead to sell cheaper versions of hepatitis C drugs that sparked pricing debate
Gilead Sciences Inc. will sell cheaper version.....»»
Gilead to Slice List Prices of Liver Drugs
The drugmaker intends to slash the list price of its hepatitis C treatments as it responds to competitive pricing pressures and shifts in the U.S. payment system for pharmaceuticals......»»
Gilead Sciences" Latest Tactic? Go Generic
The company plans to launch generic versions of its top hepatitis C drugs to insulate itself against competition......»»
This Peninsula giant wants to build a "wellbeing center" for employees
Gilead Sciences Inc. hopes to convert a parking lots on its sprawling Foster City campus into a 60,836-square-foot amenities building. The company (NASDAQ: GILD) — known for its life-changing HIV/AIDS and hepatitis C drugs and one of the first ce.....»»
With $200M in hand, Cambridge startup sets goal: no blockbuster drugs
Armed with one of the largest-ever Series A rounds, a new Cambridge startup is looking to upend the drug industry’s approach to pricing by creating competitor treatments that are “radically†cheaper......»»
Analyst says Netflix must go cheaper or lose millions of users
Netflix Inc. was downgraded to the equivalent of a sell at Needham, which reiterated its view that the video-streaming company was at risk of losing millions of customers in 2020 given competition and pricing......»»
The obscure advisory committees at the heart of the U.S. drug pricing debate
Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries......»»
He helped Gilead score billions from HIV, hepatitis C drugs — now he"s building a cancer fighter
Norbert Bischofberger rides again. The 62-year-old former chief scientific officer at Gilead Sciences Inc. (NASDAQ: GILD), who stepped down last month after overseeing the development of groundbreaking and sometimes-controversial HIV and hepatiti.....»»
What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments
There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several........»»
Gilead (GILD) to Launch Generics for Leading HCV Treatments
Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa .....»»
Gilead Is Undercutting Its Own Drugs: Here"s Why
The biotech is trying to beat the drug pricing system -- or maybe trying to change it for the better......»»
Gilead charged $1,100 a day for this drug. Now it will launch a generic at quarter the price.
A generic version of Harvoni — one in a series of life-changing hepatitis C drugs Gilead Sciences Inc. introduced four years ago at a price of over $1,000 a pill — will hit the market early next year at a quarter the price of the branded drug. But.....»»
Elon Musk Reacts To Tesla"s Pricing Debate: "Only A Fool Thinks …."
Elon Musk, the CEO of Tesla, has weighed in on the ongoing debate regarding the pricing of the company's Full Self-Driving feature. read more.....»»
A ‘beautiful’ female biker was actually a 50-year-old man using FaceApp. After he confessed, his followers liked him even more.
The middle-aged father’s big reveal sparked a debate over identity in the Internet age: ‘The only thing I’m creating is … my appearance. Everything else is me.’.....»»
Elon Musk Comes In Support Of COVID-19 Vaccines After Earlier Comments Courted Controversy
Tesla Inc (NASDAQ: TSLA) CEO Elon Musk has come in support of COVID-19 vaccines after his earlier stance on social media sparked a debate surrounding the safety of a second shot. read more.....»»
What Do Sellers Actually Want? New zavvie Report Reveals 6 Megatrends
Amidst the seemingly endless speculation and debate about the new ways of selling—including iBuyers, buy-before-you-sell bridge solutions and institutional buye.....»»
: Yogurt giant Danone to sell Chinese unit in bid to appease activist investors
The Danone board will meet on Monday to debate a response to increasing pressure from activist funds......»»
Bitcoin buyers punished by surging bond yields
Investors' love affair with bitcoin has become a double-edged sword as surging bond yields sparked a sell-off in risk assets, including bitcoin, and punished shares of companies that recently bought the cryptocurrency......»»
"This has been a problem for years": In heated public meeting, debate rages over whether city follows protocol with developments
The debate was sparked by a review of the blighting study of Grand Center's Jesuit Hall, where Neighborhood Properties wants to invest $80 million to redevelop the property into a multifamily development......»»
The lockdown trade wins Friday
Stay-at-home ETFs were among the few gainers early Friday amidst a stock sell-off sparked by tepid economic data from Europe and Asia. The Global X Cybersecurity ETF was up 0.5%, the VanEck Vect.....»»
: ‘Manufacturers and middlemen have created a vicious cycle of price increases’: Mark Cuban pledges to sell this $225 medication for $20
Americans pay $1,397 a year on average for prescription drugs and medical costs compared to $884 for Canadians......»»